Literature DB >> 17576579

Neurodegeneration involving putative respiratory neurons in Perry syndrome.

Yoshio Tsuboi1, Dennis W Dickson, Kazuki Nabeshima, Ann M Schmeichel, Zbigniew K Wszolek, Tatsuo Yamada, Eduardo E Benarroch.   

Abstract

The objective of this study was to assess the potential involvement of ventral medullary neurons implicated in respiratory rhythmogenesis and chemosensitivity in a patient with Perry syndrome (autosomal dominant parkinsonism associated with depression, weight loss and central hypoventilation). Previous neuropathologic reports in Perry syndrome demonstrated neuronal loss in the substantia nigra with no or few Lewy bodies and no tau inclusions. Neurons in the pre-Bötzinger complex (preBötC) of the ventrolateral medulla, identified by their immunoreactivity for neurokinin-1 receptors (NK-1R), play an essential role in respiratory rhythmogenesis and serotonergic neurons in the medullary raphe in respiratory chemosensitivity, but their potential involvement in Perry syndrome has not yet been addressed. We conducted clinical and neuropathologic studies including immunohistochemistry examination in a new autopsied case clinically diagnosed as Perry syndrome. Our patient presented with parkinsonism at age 41. Subsequently, all cardinal features of Perry syndrome developed. He died of respiratory failure and sepsis at age 46. Hematoxylin-eosin staining revealed no significant pathology in the medulla. However, NK-1R, tyrosine hydroxylase (TH) and tryptophan hydroxylase (TrOH) immunoreactive neurons were significantly reduced in the ventrolateral medulla compared to controls. There was also loss of serotonergic neurons in the medullary raphe and ventral medullary surface. Severe neuronal loss in the substantia nigra, without alpha-synuclein or tau pathology but with loss of NK-1R and TH immunoreactive neurons in the ventrolateral medulla, and loss of serotonergic neurons in the medullary raphe and ventrolateral medulla may be a pathologic hallmark of Perry syndrome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576579     DOI: 10.1007/s00401-007-0246-1

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  15 in total

1.  In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers.

Authors:  Andre C Felicio; Katherine Dinelle; Pankaj A Agarwal; Jessamyn McKenzie; Nicole Heffernan; Jeremy D Road; Silke Appel-Cresswell; Zbigniew K Wszolek; Matthew J Farrer; Michael Schulzer; Vesna Sossi; A Jon Stoessl
Journal:  Mov Disord       Date:  2014-05-05       Impact factor: 10.338

Review 2.  DCTN1-related neurodegeneration: Perry syndrome and beyond.

Authors:  Takuya Konno; Owen A Ross; Hélio A G Teive; Jarosław Sławek; Dennis W Dickson; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2017-06-12       Impact factor: 4.891

3.  Central hypoventilation in progressive supranuclear palsy.

Authors:  Kory S Herrick; Randy Woltjer; Thao Pham; Megan Chalupsky; Amie L Hiller
Journal:  Mov Disord Clin Pract       Date:  2016-05-19

4.  Elucidating the genetics and pathology of Perry syndrome.

Authors:  Christian Wider; Justus C Dachsel; Matthew J Farrer; Dennis W Dickson; Yoshio Tsuboi; Zbigniew K Wszolek
Journal:  J Neurol Sci       Date:  2009-09-04       Impact factor: 3.181

5.  Pallidonigral TDP-43 pathology in Perry syndrome.

Authors:  Christian Wider; Dennis W Dickson; A Jon Stoessl; Yoshio Tsuboi; Françoise Chapon; Ludwig Gutmann; Bernard Lechevalier; Donald B Calne; David A Personett; Mary Hulihan; Jennifer Kachergus; Rosa Rademakers; Matthew C Baker; Linda L Grantier; O K Sujith; Laura Brown; Susan Calne; Matthew J Farrer; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2008-08-23       Impact factor: 4.891

6.  Perry syndrome due to the DCTN1 G71R mutation: a distinctive levodopa responsive disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure.

Authors:  Victoria Newsway; Mark Fish; Jonathan D Rohrer; Elisa Majounie; Nigel Williams; Melissa Hack; Jason D Warren; Huw R Morris
Journal:  Mov Disord       Date:  2010-04-30       Impact factor: 10.338

7.  DCTN1 mutations in Perry syndrome.

Authors:  Matthew J Farrer; Mary M Hulihan; Jennifer M Kachergus; Justus C Dächsel; A Jon Stoessl; Linda L Grantier; Susan Calne; Donald B Calne; Bernard Lechevalier; Francoise Chapon; Yoshio Tsuboi; Tatsuo Yamada; Ludwig Gutmann; Bülent Elibol; Kailash P Bhatia; Christian Wider; Carles Vilariño-Güell; Owen A Ross; Laura A Brown; Monica Castanedes-Casey; Dennis W Dickson; Zbigniew K Wszolek
Journal:  Nat Genet       Date:  2009-01-11       Impact factor: 38.330

Review 8.  Clinical, pathological and genetic characteristics of Perry disease-new cases and literature review.

Authors:  Jarosław Dulski; Catalina Cerquera-Cleves; Lukasz Milanowski; Alexa Kidd; Emilia J Sitek; Audrey Strongosky; Ana María Vanegas Monroy; Dennis W Dickson; Owen A Ross; Jolanta Pentela-Nowicka; Jarosław Sławek; Zbigniew K Wszolek
Journal:  Eur J Neurol       Date:  2021-08-26       Impact factor: 6.288

9.  Neuropathology of Perry Syndrome: Evidence of Medullary and Hypothalamic Involvement.

Authors:  David Dongkyung Kim; Huda Alghefari; Mary Jenkins; Lee-Cyn Ang; Stephen H Pasternak
Journal:  Mov Disord Clin Pract       Date:  2021-05-27

Review 10.  Understanding the rhythm of breathing: so near, yet so far.

Authors:  Jack L Feldman; Christopher A Del Negro; Paul A Gray
Journal:  Annu Rev Physiol       Date:  2012-10-29       Impact factor: 22.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.